Literature DB >> 28344213

Over-Expression of TBL1XR1 Indicates Poor Prognosis of Serous Epithelial Ovarian Cancer.

Ming Ma1, Nina Yu.   

Abstract

Transducin (β)-like 1 X-linked receptor 1 (TBL1XR1) is a core component of the NCoR/SMRT transcription co-repressor complex, and its role in regulating cancer progression has been reported. Serous epithelial ovarian cancer (EOC) is the most common histological type of EOC. Here we explored the significance of TBL1XR1 expression in predicting outcomes of patients with serous EOC. Real-time quantitative PCR analysis showed that the expression level of TBL1XR1 mRNA was significantly higher in EOC tissues compared with adjacent non-tumorous tissues. The protein levels of TBL1XR1 in EOC tissues were assessed by immunohistochemistry, and the patients were classified into low-expression group (n = 62) and high-expression group (n = 54) according to the immunoreactivity. Prognostic significance of TBL1XR1 was evaluated by univariate and multivariate analyses, showing that over-expression of TBL1XR1 was correlated with poor prognosis. In addition, TBL1XR1 was positively associated with the lymph node metastasis of EOC. Because vascular endothelial growth factor (VEGF)-C is known as a critical mediator of lymph node metastasis, we measured the expression level of VEGF-C mRNA in EOC tissues and thus identified a positive correlation between TBL1XR1 and VEGF-C mRNA levels. Subsequently, using human EOC cell lines, we showed that silencing of TBL1XR1 decreased VEGF-C expression, suggesting that TBL1XR1 may function as an upstream regulator of VEGF-C in EOC. Furthermore, the proliferation and invasion of EOC cells were inhibited by TBL1XR1 silencing. In conclusion, TBL1XR1 overexpression may be an unfavorable prognostic factor for EOC. We also suggest that the TBL1XR1-VEGF-C axis may determine the EOC progression.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28344213     DOI: 10.1620/tjem.241.239

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  6 in total

1.  Transducin (β)-like 1 X-linked receptor 1 correlates with clinical prognosis and clinicopathological characteristics in human solid carcinomas.

Authors:  Fangteng Liu; Hui Gao; Yang Zhao; Zhengming Zhu
Journal:  Oncotarget       Date:  2017-06-27

2.  Prediction of the Prognosis Based on Chromosomal Instability-Related DNA Methylation Patterns of ELOVL2 and UBAC2 in PTCs.

Authors:  Jun Han; Meijun Chen; Qingxiao Fang; Yanqing Zhang; Yihan Wang; Jamaspishvili Esma; Hong Qiao
Journal:  Mol Ther Nucleic Acids       Date:  2019-10-07       Impact factor: 8.886

3.  Prognostic values of myeloid differentiation factor 88 (MYD88) and transducin (β)-like receptor 1 (TBLR1) expression in tissues of diffuse large B-cell non-Hodgkin lymphoma patients - an immunohistochemical study.

Authors:  Asmaa Hussein Mohamed; Mariem A Elfeky; Shereen Elshorbagy; Nabila Hefzi; Tamer Oraby; Waleed A Abdelhady; Mahmoud Sharaf Eldein; Ahmed Embaby; Ehab M Oraby
Journal:  Contemp Oncol (Pozn)       Date:  2022-03-30

Review 4.  Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer.

Authors:  Shuna Liu; Ming Wu; Fang Wang
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

5.  HSP90AA1, ADRB2, TBL1XR1 and HSPB1 are chronic obstructive pulmonary disease-related genes that facilitate squamous cell lung cancer progression.

Authors:  Lijing Wang; Hongjun Zhao; Lemeng Zhang; Hui Luo; Qiong Chen; Xiaoxia Zuo
Journal:  Oncol Lett       Date:  2020-01-17       Impact factor: 2.967

6.  Genetic alterations in the 3q26.31-32 locus confer an aggressive prostate cancer phenotype.

Authors:  Benjamin S Simpson; Niedzica Camacho; Hayley J Luxton; Hayley Pye; Ron Finn; Susan Heavey; Jason Pitt; Caroline M Moore; Hayley C Whitaker
Journal:  Commun Biol       Date:  2020-08-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.